+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Mannkind Corporation - logo

MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

From
From
From
Global Type 1 Diabetes Drugs Market 2021-2025 - Product Thumbnail Image

Global Type 1 Diabetes Drugs Market 2021-2025

  • Report
  • May 2021
  • 120 Pages
  • Global
From
Diabetes Drug Delivery Devices Market, 2020-2030 - Product Thumbnail Image

Diabetes Drug Delivery Devices Market, 2020-2030

  • Report
  • August 2020
  • 147 Pages
  • Global
From
Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H1, 2020 - Product Thumbnail Image

Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H1, 2020

  • Clinical Trials
  • March 2020
  • 1094 Pages
  • Global
From
From
Autoimmune Collaboration and Licensing Deals 2016-2023 - Product Thumbnail Image

Autoimmune Collaboration and Licensing Deals 2016-2023

  • Report
  • October 2023
  • 450 Pages +
  • Global
From
Loading Indicator